Recombinant Human Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) Protein (His-SUMO)
Beta LifeScience
SKU/CAT #: BLC-09774P

Greater than 90% as determined by SDS-PAGE.
Recombinant Human Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) Protein (His-SUMO)
Beta LifeScience
SKU/CAT #: BLC-09774P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein. |
Purity | Greater than 90% as determined by SDS-PAGE. |
Uniprotkb | Q96FL9 |
Target Symbol | GALNT14 |
Synonyms | GalNAc T14; GalNAc-T14; Galnt14; GLT14_HUMAN; Polypeptide GalNAc transferase 14; Polypeptide N acetylgalactosaminyltransferase 14; Polypeptide N-acetylgalactosaminyltransferase 14; pp GaNTase 14; pp-GaNTase 14; Protein UDP acetylgalactosaminyltransferase 14; Protein-UDP acetylgalactosaminyltransferase 14; UDP GalNAc:polypeptide N acetylgalactosaminyltransferase 14 ; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 14 |
Species | Homo sapiens (Human) |
Expression System | E.coli |
Tag | N-6His-SUMO |
Target Protein Sequence | MRRLTRRLVLPVFGVLWITVLLFFWVTKRKLEVPTGPEVQTPKPSDADWDDLWDQFDERRYLNAKKWRVGDDPYKLYAFNQRESERISSNRAIPDTRHLRCTLLVYCTDLPPTSIIITFHNEARSTLLRTIRSVLNRTPTHLIREIILVDDFSNDPDDCKQLIKLPKVKCLRNNERQGLVRSRIRGADIAQGTTLTFLDSHCEVNRDWLQPLLHRVKEDYTRVVCPVIDIINLDTFTYIESASELRGGFDWSLHFQWEQLSPEQKARRLDPTEPIRTPIIAGGLFVIDKAWFDYLGKYDMDMDIWGGENFEISFRVWMCGGSLEIVPCSRVGHVFRKKHPYVFPDGNANTYIKNTKRTAEVWMDEYKQYYYAARPFALERPFGNVESRLDLRKNLRCQSFKWYLENIYPELSIPKESSIQKGNIRQRQKCLESQRQNNQETPNLKLSPCAKVKGEDAKSQVWAFTYTQQILQEELCLSVITLFPGAPVVLVLCKNGDDRQQWTKTGSHIEHIASHLCLDTDMFGDGTENGKEIVVNPCESSLMSQHWDMVSS |
Expression Range | 1-552aa |
Protein Length | Full Length |
Mol. Weight | 80.3kDa |
Research Area | Metabolism |
Form | Liquid or Lyophilized powder |
Buffer | Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. |
Reconstitution | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
Storage | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
Notes | Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week. |
Target Details
Target Function | Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Displays activity toward mucin-derived peptide substrates such as Muc2, Muc5AC, Muc7, and Muc13 (-58). May be involved in O-glycosylation in kidney. |
Subcellular Location | Golgi apparatus membrane; Single-pass type II membrane protein. |
Protein Families | Glycosyltransferase 2 family, GalNAc-T subfamily |
Database References | |
Tissue Specificity | Detected in renal tubules (at protein level). Highly expressed in fetal and adult kidney. Widely expressed at low level. Weakly expressed in whole brain, cerebellum, thymus, lung, mammary gland, liver, stomach, small intestine, colon, pancreas, spleen, bl |
Gene Functions References
- Silencing of GALNT14 in osterix-overexpressed cells restored the decreased chemosensitivity. Conversely, overexpression of GALNT14 in osterix-knockdown cells abrogated the increased chemosensitivity in breast cancer cells. PMID: 29227978
- The analysis showed that the "TT" genotype was associated with unfavorable overall survival (OS, P = 0.009). PMID: 27124048
- miR-125a functions as tumor suppressor in ovarian cancer by targeting GALNT14. PMID: 27133078
- GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. PMID: 26871639
- Expression of GalNAc-T14 or HOXB9 was strongly correlated with reduced recurrence-free survival in lung adenocarcinomas. PMID: 26544896
- Recurrence of mutation suggests GALNT14 as a novel gene potentially involved in neuroblastoma predisposition. PMID: 26309160
- GALNT14 stimulates MMP-2 expression. PMID: 24962947
- GALN14 genotype (rs9679162) was an effective predictor for therapeutic outcome in advanced hepatocellular carcinoma (HCC) patients treated by FMP chemotherapy. PMID: 23959947
- Studies demonstrate that IGFBP-3 and GalNAc-T14 are colocalized in MCF-7 cells, and confirmed the interaction between IGFBP-3 and GalNAc-T14; these results reveal a minimal region of GalNAc-T14 that was sufficiently bound to the full-length IGFBP-3. PMID: 22441125
- Results provide evidence that GalNAc-T14 may be a potential biomarker for breast cancer by immunohistochemistry. PMID: 20356418
- GALNT14 and FUT3/6 H-scores were significantly higher in non-small cell lung cancer cell lines sensitive to dulanermin and drozitumab versus resistant cell lines PMID: 20179215
- cloning and characterization; results provide evidence that pp-GalNAc-T14 is a new member of the pp-GalNAc-T family and suggest that it may be involved in the O-glycosylation in kidney PMID: 12507512
- The role of GalNAc-T14 as an intracellular mediator of the effects of IGFBP-3 need to be verified in future studies. PMID: 17434446
- GALNT14 may be involved in regulating the apoptotic action of IGFBP-3. PMID: 19805900